Cardiothoracic & vascular anesthesia
Transplantation of initially rejected donor lungs using ex vivo lung perfusion: A 5‐year experience
Authors' conclusion
Long-term survival was significantly lower, and lung function was poorer among recipients in the EVLP group than in the non-EVLP group.
Study context
- Population
- Consecutive lung transplant recipients, May 2012 to May 2017, follow-up until July 2021
- Participants
- 157 recipients
- Exposure
- Ex vivo lung perfusion (EVLP)-treated vs non-EVLP donor lungs
- EVLPn = 39
- Outcome
- Time to graft failure (time from surgery to death or re-transplantation, whichever first)
Methodological detailsconsecutive patients, single-country experience
- Consecutive patients
- Single-country experience
Main finding
As reported in the abstract
Graft survival (time from surgery to death or re-transplantation) · up to 7 years
non-EVLP
5.14
restricted mean · years
EVLP
4.19
restricted mean
Each group vs non-EVLPDifference in restricted mean graft survival time (CI)P value
EVLP
−0.95(−1.93 to 0.04)
P = 0.059Each group vs non-EVLPHR for graft failure (CI)P value
EVLP
1.66(1.00–2.75)
P = 0.046Observational data: associations, not effects.
Secondary outcomes
- 5-year graft survival by EVLP era (subgroup) · 5 years — non-EVLP
- 60.8%
- 5-year graft survival by EVLP era (subgroup): EVLP 2012-2013 14.3%
- 5-year graft survival by EVLP era (subgroup): EVLP 2016-2017 60.0%
Freedom from chronic lung allograft dysfunction · 12 and 24 months
- Significant difference at 12 months
- P = 0.005
- Significant difference at 24 months
- P = 0.030
Causes of mortality
- Chronic lung allograft dysfunction the highest contributor to mortality in both groups
Original publication
Transplantation of initially rejected donor lungs using ex vivo lung perfusion: A 5‐year experience. Acta Anaesthesiol Scand. Published 16 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →